Asia - More Than 61% Of Hepatitis E Cases Occured In Asia, WHO Study

New research funded by the World Health Organization (WHO) estimates that 20.1 million individuals were infected with hepatitis E virus (HEV) genotypes 1 and 2 across nine world regions in 2005.

According to findings available in the April issue of the journal Hepatology, there were 3.4 million symptomatic cases, 70,000 deaths, and 3,000 stillbirths from HEV that year in countries throughout Asia and Africa.

Unlike hepatitis virus B and C strains that lead to chronic disease states, HEV causes acute illness.

Previous studies show HEV genotypes 1 and 2 specifically infect humans, and are associated with large outbreaks in developing countries where sanitation conditions are poor. There is evidence that HEV increases mortality risk among pregnant women.

“Our study represents the first attempt to estimate the annual global impact of hepatitis E,” said lead author Dr. David Rein of the social science research organization NORC at the University of Chicago.

Estimates were created by modeling the disease burden of HEV genotypes 1 and 2 in the 9 regions, representing 71 percent of the world’s population. Based on published evidence the team – a collaboration between researchers from NORC, WHO, and RTI International – also estimated annual incidence of infection to determine symptomatic, asymptomatic, and mortality cases.

Of the more than 20 million people infected with HEV, 61 percent of the cases occurred in East and South Asia, two regions which also accounted for 65 percent of deaths from HEV.

The average age of infection was 17 years with the lowest age of infection in North Africa (8 years) and highest in East Asia (21 years).

The authors caution there are limitations to the study which only estimated incidence of HEV genotypes 1 and 2, leaving out genotype 3 that prevalently occurs in Europe and the U.S., and genotype 4.

“Future HEV estimates should include genotypes 3 and 4 to provide a complete picture of the global burden of HEV,” Rein said.

In January this year, China approved the world’s first hepatitis E virus (HEV) vaccine, said the Chinese Ministry of Science and Technology. The HEV 239 vaccine, sold under the trade name Hecolin™, was developed by a team of researchers from Xiamen University and Xiamen Innovax Biotech Co. Ltd. in China’s Fujian province.

Samantha Chan

AsianScientist

Source: Wiley-Blackwell.

Business & Investment Opportunities 
YourVietnamExpert is a division of Saigon Business Corporation Pte Ltd, Incorporated in Singapore since 1994. As Your Business Companion, we propose a range of services in Strategy, Investment and Management, focusing Healthcare and Life Science with expertise in ASEAN. We also propose Higher Education, as a bridge between educational structures and industries, by supporting international programmes. Many thanks for visiting www.yourvietnamexpert.com and/or contacting us at contact@yourvietnamexpert.com

Japan - Excessive vitamin E leads to osteoporosis?

TOKYO: Japanese scientists say they have found a link between consumption of vitamin E and the degenerative bone condition osteoporosis, in a study likely to shed new light on the use of supplements.

Researchers found that giving mice increased doses of the vitamin to a level similar to that found in supplements caused the animals' bones to thin.

The mice developed osteoporosis after eight weeks on the diet, which had levels of vitamin E significantly higher than those found in a mouse's natural diet, according to the study, published in the journal Nature Medicine.

The team, led by Shu Takeda of Keio University, said vitamin E stimulates the generation of bone-degrading cells, which normally work with bone-forming cells to maintain bone strength.

Osteoporosis is a disease that causes the thinning of bone tissue and loss of bone density over time. It often affects older people, particularly women, who may become more prone to bone fractures.

Vitamin E is found naturally in various foods including vegetable oil, nuts and some leafy vegetables.

It is also a popular health supplement as an antioxidant, and is widely believed to enhance health and slow problems related to ageing.

The study called for greater research into how enhanced levels of vitamin E affect human health.

"It is possible that with the volume (of vitamin E) contained in health supplements, bones may become fragile," Takeda told the Mainichi Shimbun newspaper.

The findings come after researchers found mice that had been genetically modified to be deficient in vitamin E had a high bone density.

- AFP/fa


Business & Investment Opportunities

YourVietnamExpert is a division of Saigon Business Corporation Pte Ltd, Incorporated in Singapore since 1994. As Your Business Companion, we propose a range of services in Consulting, Investment and Management, focusing three main economic sectors: International PR; Healthcare & Wellness;and Tourism & Hospitality. We also propose Higher Education, as a bridge between educational structures and industries, by supporting international programs. Sign up with twitter to get news updates with @SaigonBusinessC. Thanks.

USA - Vitamin E "ups prostate cancer risk"

WASHINGTON: US researchers warned Tuesday of an alarming link between vitamin E supplements and a 17 per cent increased risk of prostate cancer, describing the findings as an "important public health concern".

Ten years after the start of a randomised trial of more than 35,000 men, researchers discovered the spike in prostate cancer among those assigned to take vitamin E rather than selenium or a placebo.

"Dietary supplementation with vitamin E significantly increased the risk of prostate cancer among healthy men," said the study in the Journal of the American Medical Association.

Selenium, a trace mineral found in foods like Brazil nuts, tuna and beef, is often deficient in areas such as China and Russia where it is lacking in the soil.

The study was launched based on previous research that had suggested that selenium or vitamin E might reduce the risk of developing prostate cancer.

The latest data emerged three years after a preliminary study of the findings, published in 2008, showed a slightly higher but statistically insignificant risk of prostate cancer among those taking vitamin E.

However, since the risk was approaching statistical significance, a safety committee called for a halt to the randomised Selenium and Vitamin E Cancer Prevention Trial (SELECT) in the United States, Canada and Puerto Rico in 2008.

A longer-term follow up, concluded in July of this year, has revealed the higher cancer incidence in men assigned to the vitamin E portion of the trial.

"Based on these results and the results of large cardiovascular studies using vitamin E, there is no reason for men in the general population to take the dose of vitamin E used in SELECT as the supplements have shown no benefit and some very real risks," said Eric Klein, a study co-chair for SELECT, and a physician at the Cleveland Clinic.

"For now, men who were part of SELECT should continue to see their primary care physician or urologist and bring these results to their attention for further consideration."

The study began in 2001 and broke participants into four groups: one would receive selenium, another would get 400 international units of daily vitamin E, another group would take both, and the fourth was prescribed a placebo.

A total of 620 men in the vitamin E group developed prostate cancer, as did 555 in the combined selenium and vitamin E group.

Those taking selenium only saw 575 develop prostate cancer, compared to 529 on the sugar pill.

"The observed 17 per cent increase in prostate cancer incidence demonstrates the potential for seemingly innocuous yet biologically active substances such as vitamins to cause harm," said the study.

Men entering the trial had no signs of prostate cancer and were considered to exhibit average risk of developing the disease, which is the second most common cancer among US men, after skin cancer.

According to the American Cancer Society, 240,890 new cases of prostate cancer will be diagnosed in 2011 and 33,720 men will die of prostate cancer in the United States.

The study found no biological explanation for why vitamin E was driving the risk higher, but warned that the effects of the pills may continue even after the patient stops taking them.

"The fact that the increased risk of prostate cancer in the vitamin E group of participants in SELECT was only apparent after extended follow-up... suggests that health effects from these agents may continue even after the intervention is stopped," it said.

The findings also "underscore the need for consumers to be sceptical of health claims for unregulated over-the-counter products in the absence of strong evidence of benefit demonstrated in clinical trials," it said.

The trial was funded by the National Cancer Institute, the National Centre for Complementary and Alternative Medicine, the National Heart, Lung, and Blood Institute, the National Institute of Aging and the National Eye Institute.

- AFP/wk


Business & Investment Opportunities
YourVietnamExpert is a division of Saigon Business Corporation Pte Ltd, Incorporated in Singapore since 1994. As Your Business Companion, we propose a range of services in Consulting, Investment and Management, focusing three main economic sectors: International PR; Healthcare & Wellness;and Tourism & Hospitality. We also propose Higher Education, as a bridge between educational structures and industries, by supporting international programs. Sign up with twitter to get news updates with @SaigonBusinessC. Thanks.